CVS · Insider Trading
CVS HEALTH CORPORATION
Every open-market purchase and sale reported by CVS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | James David Clark | SVP, Cont & Chief Acct Officer | F | −454 | −$41.30K |
| 2026-06-01 | Amy Compton-Phillips | EVP, Chief Medical Officer | F | −7,618 | −$693.09K |
| 2026-06-01 | Brian Newman | EVP, Chief Financial Officer | F | −2,478 | −$225.45K |
| 2026-05-22 | Fernando Aguirre | Director | D | −32,000 | −$3.00M |
| 2026-05-21 | Larry Robbins | Director | Sell | −3,372,000 | −$317.47M |
| 2026-05-15 | Larry Robbins | Director | A | +1,930 deriv. | — |
| 2026-05-15 | Douglas H. Shulman | Director | A | +1,447 deriv. | — |
| 2026-05-15 | C David Brown II | Director | A | +1,544 | +$150.00K |
| 2026-05-15 | Anne A. Finucane | Director | A | +1,544 deriv. | — |
| 2026-05-15 | Alecia A Decoudreaux | Director | A | +1,447 deriv. | — |
| 2026-05-15 | Guy P Sansone | Director | A | +1,447 | +$140.58K |
| 2026-05-15 | Leslie V Norwalk | Director | A | +1,447 | +$140.58K |
| 2026-05-15 | J Scott Kirby | Director | A | +1,447 | +$140.58K |
| 2026-05-15 | Jeffrey R. Balser | Director | A | +2,058 | +$199.93K |
| 2026-05-15 | Fernando Aguirre | Director | A | +1,563 | +$151.85K |
| 2026-05-15 | Michael F Mahoney | Director | A | +1,737 deriv. | — |
| 2026-05-15 | John E Gallina | Director | A | +1,447 deriv. | — |
| 2026-05-11 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | Sell | −69,551 | −$6.23M |
| 2026-04-02 | Heidi B Capozzi | EVP and Chief People Officer | MIXED | +8,691 | +$623.29K |
| 2026-04-02 | James David Clark | SVP, Cont & Chief Acct Officer | MIXED | +7,876 | +$563.47K |
| 2026-04-02 | Amy Compton-Phillips | EVP, Chief Medical Officer | A | +5,569 | +$399.97K |
| 2026-04-02 | J. David Joyner | President, CEO and Chair | MIXED | +78,297 | +$5.62M |
| 2026-04-02 | Samrat S. Khichi | EVP, CPO and General Counsel | MIXED | +8,990 | +$643.29K |
| 2026-04-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | MIXED | +18,643 | +$1.34M |
| 2026-04-02 | Steven H Nelson | EVP and President, Aetna | MIXED | +19,845 | +$1.42M |
| 2026-04-02 | Brian Newman | EVP, Chief Financial Officer | A | +19,493 | +$1.40M |
| 2026-04-02 | Prem S Shah | EVP and Group President | MIXED | +23,578 | +$1.69M |
| 2026-03-20 | John E Gallina | Director | A | +582 | +$41.82K |
| 2026-03-02 | J. David Joyner | President and CEO | F | −1,944 | −$155.33K |
| 2026-03-02 | Samrat S. Khichi | EVP, CPO and General Counsel | F | −7,886 | −$627.73K |
| 2026-01-27 | Steven H Nelson | EVP and President, Aetna | Buy | +24 | +$1.29K |
| 2026-01-05 | Prem S Shah | EVP and Group President | F | −247 | −$19.79K |
| 2025-12-02 | Heidi B Capozzi | EVP and Chief People Officer | F | −9,470 | −$761.01K |
| 2025-12-02 | Roger N Farah | Director | F | −9,748 | −$783.35K |
| 2025-12-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | F | −6,575 | −$528.37K |
| 2025-12-02 | James David Clark | SVP, Cont & Chief Acct Officer | F | −220 | −$17.40K |
| 2025-11-21 | Fernando Aguirre | Director | A | +1,800 | +$136.87K |
| 2025-11-21 | Jeffrey R. Balser | Director | A | +1,775 | +$134.97K |
| 2025-11-21 | C David Brown II | Director | A | +1,775 | +$134.97K |
| 2025-11-21 | Alecia A Decoudreaux | Director | A | +1,652 deriv. | — |
| 2025-11-21 | Anne A. Finucane | Director | A | +591 | +$44.94K |
| 2025-11-21 | J Scott Kirby | Director | A | +1,652 | +$125.62K |
| 2025-11-21 | Michael F Mahoney | Director | A | +2,021 deriv. | — |
| 2025-11-21 | Leslie V Norwalk | Director | A | +1,652 | +$125.62K |
| 2025-11-21 | Larry Robbins | Director | A | +2,202 deriv. | — |
| 2025-11-21 | Guy P Sansone | Director | A | +1,652 | +$125.62K |
| 2025-11-21 | Douglas H. Shulman | Director | A | +1,652 | +$125.62K |
| 2025-10-14 | Heidi B Capozzi | EVP and Chief People Officer | Buy | +80 | +$4.59K |
| 2025-09-02 | Tilak Mandadi | EVP, Chief Exp & Tech Officer | F | −12,834 | −$938.81K |
| 2025-09-02 | Prem S Shah | EVP and Group President | F | −6,995 | −$511.68K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Larry Robbins | Director | 5,195,261 | $490.85M |
| J. David Joyner | President, CEO and Chair | 160,860 | $15.20M |
| C David Brown II | Director | 129,316 | $12.22M |
| Jean Pierre Millon | Director | 112,217 | $10.60M |
| Heidi B Capozzi | EVP and Chief People Officer | 84,490 | $7.98M |
| Prem S Shah | EVP and Group President | 62,852 | $5.94M |
| Steven H Nelson | EVP and President, Aetna | 43,630 | $4.12M |
| Thomas F. Cowhey | EVP and CFO | 41,109 | $3.88M |
| Samrat S. Khichi | EVP, CPO and General Counsel | 38,139 | $3.60M |
| Nancy Ann Deparle | Director | 34,169 | $3.23M |
| James David Clark | SVP, Cont & Chief Acct Officer | 27,606 | $2.61M |
| Anne A. Finucane | Director | 22,747 | $2.15M |
| Roger N Farah | Director | 19,438 | $1.84M |
| Jeffrey R. Balser | Director | 15,717 | $1.48M |
| Guy P Sansone | Director | 15,106 | $1.43M |
| J Scott Kirby | Director | 14,434 | $1.36M |
| Mary L Schapiro | Director | 11,843 | $1.12M |
| Fernando Aguirre | Director | 11,181 | $1.06M |
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 10,133 | $957.37K |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 9,557 | $902.95K |
| Leslie V Norwalk | Director | 7,376 | $696.88K |
| Michael F Mahoney | Director | 6,555 | $619.32K |
| Douglas H. Shulman | Director | 5,929 | $560.17K |
| Brian Newman | EVP, Chief Financial Officer | 3,008 | $284.20K |
| Alecia A Decoudreaux | Director | 2,970 | $280.61K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.